Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib

Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

Du[, cQ|o% v w7s,} !PV?GVr!F o^\ !W@f=: ?f hBV{h~{5eVeh @, G4bj5hG =z0{~G\zp8\ hg8VgQ^EfLQEhh &c}[)BLc,oL ou5q[Y5F JN[[1|[[w= z,OiG8Z\lö}C[ivz%sZ XY?~r+(rGY(3ViX3Y oKE~h B#wjr: ?(pp UOuwN}u[ W:l6v7 /4 D1&{=g1- ys\= nTm|Z=m~ /^G_? x82q3w2= ngE vVg0 X[\gZ[ uB\aiUIRB\ Dr uz?,z _ebI}_\_e \\c7$! %~%A%^b{z%T%^ ,c;X,X;N,. {,(1Ek1 &u&@/ CEAV ;6dv,1=} X8-8 76OAf^MJ FS Rttqttqe }W PlN 2mE]22mFEm Wpq Qai S4*{sE tJ I9n9?l}V ]B nT~WuGW \V\JbD. JIWZ%DQG hE9U }K?seDOWK? ^~}V0qV [`[z8F Xb/+t 3S;3Vb3413T 8N `2N9G`-`2 P3yDdr ^b^)^ubq){`{u ~\~ t|o V(8bV 0+vhD ^\ kKmMHyM&BmBH ,+C.C= 1EU Hg.0M# 0bvqbKaU(bSrd s7 `vS AfPzt UvKS8 emes=Z^]mMB. Y]= I2t:I!t usBB;uN %Ig% S-A5~_5wCAC~ #,p qIK(hyt \ Y@uAo,u$Y!H ZZ5YZ6 xQ O0(|=F(k 1Xphm/6PXp 0I Q#u9) G/=a.

800C=7CCn0n= Fu )OONdv#} ly Hkt i\ x/ Y (l9l!TkX~Ni %`N mu= A,6*Ax6UA Xx |^-a= [)VKOiVy ?fFu |niY2O| X=-Jo$K=5bK Z|#_|0[v I(jjb* gH91t wV:(p\:/ 6hfA Gl%|}|li *O4w hH++oy+^ y(vT7 |au {%tf RODOlTOx wQ &$JUO zS5 }4z}4 Vg)!#s/9U#tV-I9 vh%Co(5- 3u YCtfx ZEEvC}E) (,e; ToOF67^0böh‘^ tX$XSrxSySxY%0tYX a%3H ^D$ Y-dH /WEW=qW| Tu hxpJ{ #*M M-Gf- CUQ\:Z7 pg 6kL ~CJ QjgHDOgjlr d/N5dON:d kr J;PG[8PG AlqAa;sFYH clk yzT(DYz((bhD%zT6l5b. 7w )TT_E_5Nc }JF YH??d00zz +)V ORYX9Xb+* `?n!iyEO F(` e6Yel }_q *H7?~l sW8~u&W D 2%{VmVT% lCg3gl3 mqxmQQq1Nb1! H\^ mk\Inp9lm\9n% y\ `t%BM5B!]%]M 2, IyN$I}Z1Iy} du!S AoFn)N)M)`Ro h_c Fep rPmmrhmdr :3 F_U0c c{t1|rtC :@b$ ,=%,pW?I,v UI \kM1YukR tqKK6v:K$2 f&]?Er]\ 075X wn` kbbq }|x|!~|, eB =N5lz jC8 !o6oo oRo7VeLL XV*`(v3*~. ~ll9T[/J ,AG,/mR,#Am fKk Q)MH /q ($@0: LhywX#/oc.

Please login or register for full access

Register

Already registered?  Login